Aurobindo arm CuraTeQ Biologics gets GMP certificate from EMA
The Hindu
Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three products.
Aurobindo Pharma subsidiary CuraTeQ Biologics has received a GMP certificate of compliance for its biosimilars manufacturing facility from the European Medicines Agency (EMA).
The GMP inspection, conducted by EMA representatives from April 8-12, assessed mammalian and microbial drug substance manufacturing facility sections, prefilled syringes and vials filling, packaging and QC testing and release laboratories.
This inspection outcome paves way for securing approvals for three biosimilars in Europe, currently under review by the Agency, within the next two to five months, Aurobindo Pharma Director and CEO of Biologics, Vaccines and Peptides Satakarni Makkapati said in a release on Tuesday (November 12, 2024).
“Our portfolio comprises 14 biosimilars in development across oncology and immunology segments. We are dedicated to building a sustainable biosimilars portfolio and bringing these essential therapies to patients,” Vice-Chairman and Managing Director of Aurobindo Pharma K. Nithyananda Reddy said.
Equity markets decline on weak earnings, global trends; inflation hits 14-month high, foreign funds exit, oil prices rise.
Swiggy IPO debuts with a 7.69% jump at NSE, market valuation at ₹89,549.08 crore; shares listed at ₹412 on BSE.
Shares in Samsung Electronics fell on Wednesday to their lowest level in more than four years.
Mercedes-Benz India introduces the new Mercedes-AMG C 63 S E Performance sportscar with hybrid powertrain and innovative business model.
Hyundai Motor India Ltd. reports 16% profit decline in Q3 due to market sentiments, geopolitical factors, and Red Sea crisis.
Equity market plunges over 800 points, eroding market capitalisation by ₹5.29 lakh crore amid global economic concerns.
Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three products.
BCCI to withdraw insolvency plea against Byju's after Supreme Court sets aside NCLAT judgement, NCLT hearing scheduled.
Natco Pharma's Q2 profits soar 83% to ₹676.5 crore, driven by robust exports and stable domestic business.
India's industrial output rebounds with 3.1% growth in September, led by manufacturing, despite weak electricity and mining sectors.
India's retail inflation hits 6.2% in October, driven by a 10.9% spike in food prices, breaching RBI's upper limit.